1. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

antigen-presenting cell

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

1

Fluorescent Dye

2

Biochemical Assay Reagents

2

Peptides

3

Inhibitory Antibodies

4

Natural
Products

2

Recombinant Proteins

14

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99933

    IMP321; LAG-3Ig

    LAG-3 Cancer
    Eftilagimod alfa (IMP321) is a recombinant LAG-3Ig fusion protein that binds to MHC class II. Eftilagimod alfa mediates antigen-presenting cell (APC) activation followed by CD8 T-cell activation. Eftilagimod alfa can be used for metastatic melanoma and metastatic breast carcinoma research .
    Eftilagimod alfa
  • HY-P5623B

    RVG29 TFA; RDP TFA; Rabies Virus Glycoprotein-29 TFA

    Bacterial Infection
    RVG TFA is a peptide derived from Rabies Virus Glycoprotein that binds to the α-7 subunit of nicotinic acetylcholine receptors (AchR) of neuronal cells. RVG enhances delivery of Mycobacterium tuberculosis antigens to antigen-presenting cells .
    RVG TFA
  • HY-P99742

    ADC-1013; JNJ-64457107

    TNF Receptor Cancer
    Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment .
    Mitazalimab
  • HY-163028

    Tim3 Cancer
    ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1. ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab (HY-P9903A). ML-T7 can be used for tumor immunotherapy research .
    ML-T7
  • HY-101092
    QS-21
    3 Publications Verification

    Stimulon

    NOD-like Receptor (NLR) Inflammation/Immunology Cancer
    QS-21, an immunostimulatory saponin, could be used as a potent vaccine adjuvant. QS-21 stimulates Th2 humoral and Th1 cell-mediated immune responses through action on antigen presenting cells (APCs) and T cells. QS-21 can activate the NLRP3 inflammasome with subsequent release of caspase-1 dependent cytokines, IL-1β and IL-18 .
    QS-21
  • HY-112758
    DLin-KC2-DMA
    4 Publications Verification

    Liposome Others
    DLin-KC2-DMA is an ionisable cationic lipid (pKa≈6) that is virtually non-toxic to antigen presenting cells (APCs). DLin-KC2-DMA produces significant siRNA-mediated gene silencing of GAPDH, when binds to lipid nanoparticles (LNP). DLin-KC2-DMA can be used in siRNA delivery studies .
    DLin-KC2-DMA
  • HY-151509

    Others Cancer
    A2-Iso5-2DC18 is a dihydroimidazole-linked lipid, served as potent mRNA delivery vehicle. A2-Iso5-2DC18 can be used for antitumor research, including B16F10 melanoma. .
    A2-Iso5-2DC18
  • HY-P5623

    RVG29; RDP; Rabies Virus Glycoprotein-29

    Bacterial Infection
    RVG (RVG29) is a peptide derived from Rabies Virus Glycoprotein that binds to the α-7 subunit of nicotinic acetylcholine receptors (AchR) of neuronal cells. RVG enhances delivery of Mycobacterium tuberculosis antigens to antigen-presenting cells .
    RVG

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: